Table 2 Serum proNGF levels, grouped by demographic and disease classification. Differences between groups are assessed using Pearson’s Chi-Square test (binary classification at the 1 ng/mL limit of detection) and Wilcoxon Rank-Sum test (continuous)
Category | Serum proNGF (dichotomised) | Serum proNGF (continuous) | Multiple logistic regression* | |||
|---|---|---|---|---|---|---|
n > 1 ng/mL/n in group | p-value | Median (IQR) | p-value | OR (95% CI) | p-value | |
Overall | 28/204 (14%) | Â | Â | Â | Â | Â |
 By malignancy status | 0.88 |  | 0.97 | 1.0 (0.4–2.7) | 0.98 | |
  -Thyroid cancer | 6/46 (13%) |  | 0 (0–0) |  | ||
  -Benign thyroid diseases | 22/158 (14%) |  | 0 (0–0) |  | ||
 By thyroid hormone status | 0.002 |  | 0.002 | 3.3 (1.3–8.7) | 0.02 | |
  -Hyperthyroid | 9/28 (32%) |  | 0 (0–1.74) |  | ||
  -Euthyroid | 19/176 (11%) |  | 0 (0–0) |  | ||
 By follicular lesion | 0.93 |  |  |  |  | |
  -Present | 3/21 (14%) |  | 0 (0–0) | 0.80 | 1.1 (0.3–4.2) | 0.88 |
  -Absent | 25/183 (14%) |  | 0 (0–0) |  | ||
 By age | 0.20 |  | 0.11 | 1.0 (1.0–1.0) | 0.18 | |
  -Age < 55 | 18/108 (17%) |  | 0 (0–0) |  | ||
  -Age ≥ 55 | 10/96 (10%) |  | 0 (0–0) |  | ||
 By sex | 0.53 |  | 0.54 | 0.7 (0.3–1.8) | 0.44 | |
  -Female | 21/162 (13%) |  | 0 (0–0) |  | ||
  -Male | 7/42 (17%) |  | 0 (0–0) |  | ||